Daniel Sterman
About Daniel Sterman
Daniel Sterman is the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine at NYU Langone Medical Center and a Professor of Medicine and Cardiothoracic Surgery at NYU School of Medicine.
Academic Positions at NYU Langone Medical Center
Daniel Sterman holds the position of Thomas And Suzanne Murphy Professor Of Pulmonary And Critical Care Medicine at NYU Langone Medical Center. His tenure began in 2015 at the Greater New York City Area. He also serves as the Professor of Medicine and Cardiothoracic Surgery. Additionally, he is the Division Director for Pulmonary, Critical Care, and Sleep Medicine at NYU Langone Health, again starting from 2015.
Academic and Medical Roles at University of Pennsylvania
Prior to his roles at NYU, Daniel Sterman worked at the University of Pennsylvania Medical Center and University of Pennsylvania Health System as an Associate Professor of Medicine and Surgery from 1997. He also served as an Associate Professor of Medicine at the University of Pennsylvania School of Medicine from 1996 to 2014, a span of 18 years.
Educational Background
Daniel Sterman earned his M.D. from Cornell University Medical College, where he studied from 1985 to 1989. Before that, he achieved an A.B. in Russian History and Foreign Policy from Brown University, where he studied from 1981 to 1985.
Clinical Trials and Research Initiatives
Daniel Sterman has been involved in several significant clinical trials and research initiatives. He led the development of a Phase I/II clinical trial involving intrapleural delivery of the interferon-alpha gene via adenoviral vector, combined with standard chemotherapy and COX-2 inhibition. He also conducted multiple Phase II Clinical Trials evaluating patient-specific lung cancer vaccines, and a trial using a gene-modified Listeria monocytogenes vector expressing human Mesothelin as a vaccine for advanced mesothelioma patients.
Collaborations and Research Leadership
Daniel Sterman has worked closely with Dr. Harvey Pass, Chief of Thoracic Surgery, to develop multidisciplinary translational research programs in lung cancer and mesothelioma at NYU. He was the lead clinical investigator in the Thoracic Oncology Research Group at Penn and serves as the Principal Investigator of Project 1 for the NCI Program Project Grant for Immunotherapy of Malignant Mesothelioma, which has been continuously funded since 1998.